Charles River Laboratories International Inc (CRL): George Massaro , director of Charles River Laboratories International Inc sold 800 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $83.54 per share for a total value of $66,831.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 5, 2016, George Massaro (director) sold 3,740 shares at $83.06 per share price.On May 25, 2016, John J Crowley (SVP, Chief Accounting Officer) sold 1,913 shares at $85.00 per share price.Also, On May 16, 2016, Richard F Wallman (director) sold 1,970 shares at $82.34 per share price.On Apr 8, 2016, Davide Molho (Corporate Executive VP) sold 30,667 shares at $80.00 per share price.
Charles River Laboratories: On Friday, Jul 1, 2016 heightened volatility was witnessed in Charles River Laboratories which led to swings in the share price. The shares opened for trading at $82.59 and hit $83.88 on the upside , eventually ending the session at $83.3, with a gain of 1.04% or 0.86 points. The heightened volatility saw the trading volume jump to 3,02,063 shares. The 52-week high of the share price is $87.95 and the company has a market cap of $3,930 M . The 52-week low of the share price is at $59.99.
Company has been under the radar of several Street Analysts.Charles River Laboratories is Initiated by Credit Suisse to Neutral and the brokerage firm has set the Price Target at $84. The Rating was issued on Jun 21, 2016.Charles River Laboratories is Reiterated by Barclays to Underweight and the brokerage firm has raised the Price Target to $ 65 from a previous price target of $60 .The Rating was issued on May 20, 2016.Charles River Laboratories is Initiated by Gabelli & Co to Buy and the brokerage firm has set the Price Target at $96. The Rating was issued on Apr 26, 2016.
Charles River Laboratories International Inc. is a full service early stage contract research company. The Company offers research models for the research and development of new drugs devices and therapies. It develops a portfolio of discovery and safety assessment services both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS) which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA) which provides services that enables the clients to outsource their drug discovery research critical regulatory-required safety assessment testing and related drug discovery and development activities and Manufacturing Support (Manufacturing) which is involved in the production and release of products manufactured by the clients.